Results for: Companion Diagnostic

Illumina, Inc. (ILMN) has secured FDA approval for its TruSight Oncology Comprehensive (TSO Comprehensive) test and its first two companion diagnostic (CDx) indications. This comprehensive test analyzes over 500 genes in a patient’s solid tumor, aiding in identifying biomarkers that guide targeted therapies and clinical trial enrollment. The approvals mark a significant milestone for Illumina’s oncology customers and community. The test is also approved for use in Europe.

Adial Pharmaceuticals has partnered with Boudicca Dx to develop a companion diagnostic test for AD04, a potential treatment for Alcohol Use Disorder. The test will be validated to FDA guidelines and is expected to help identify and recruit patients for the upcoming Phase 3 study of AD04.